Anti-SKP2 antibody [EPR3305(2)],Abcam,AB183039

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse, Rat, Human

Application

WB, ICC/IF, IHC-P, Flow Cyt (Intra)

Platform ID

BAB847105132

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-SKP2 antibody [EPR3305(2)]
Cat. No.AB183039
HostRabbit
IsotypeIgG
ReactivityMouse, Rat, Human
ApplicationWB, ICC/IF, IHC-P, Flow Cyt (Intra)
ClonalityMonoclonal
Clone NumberEPR3305(2)
Concentration0.323 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription (PubMed : 11931757, PubMed : 12435635, PubMed : 12769844, PubMed : 12840033, PubMed : 15342634, PubMed : 15668399, PubMed : 15949444, PubMed : 16103164, PubMed : 16262255, PubMed : 16581786, PubMed : 16951159, PubMed : 17908926, PubMed : 17962192, PubMed : 22464731, PubMed : 22770219, PubMed : 32267835). Specifically recognizes phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition (By similarity). Degradation of CDKN1B/p27kip also requires CKS1 (By similarity). Recognizes target proteins ORC1, CDT1, RBL2, KMT2A/MLL1, CDK9, RAG2, NBN, FOXO1, UBP43, YTHDF2, and probably MYC, TOB1 and TAL1 (PubMed : 11931757, PubMed : 12435635, PubMed : 12769844, PubMed : 12840033, PubMed : 15342634, PubMed : 15668399, PubMed : 15949444, PubMed : 16103164, PubMed : 16581786, PubMed : 16951159, PubMed : 17908926, PubMed : 17962192, PubMed : 22464731, PubMed : 32267835). Degradation of TAL1 also requires STUB1 (PubMed : 17962192). Recognizes CDKN1A in association with CCNE1 or CCNE2 and CDK2 (PubMed : 16262255). Promotes ubiquitination and destruction of CDH1 in a CK1-dependent manner, thereby regulating cell migration (PubMed : 22770219). Following phosphorylation in response to DNA damage, mediates 'Lys-63'-linked ubiquitination of NBN, promoting ATM recruitment to DNA damage sites and DNA repair via homologous recombination (PubMed : 22464731).. Through the ubiquitin-mediated proteasomal degradation of hepatitis C virus non-structural protein 5A, has an antiviral activity towards that virus. See full target information SKP2

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.